October 22, 2020

Evaluating Microbiome Therapies with Intestinal Cell Models

The microbiome has been shown to play roles in many different disease processes and is implicated in many more, from infectious and gastrointestinal diseases to autoimmune and neurological disorders. Advanced models of the gut leveraging intestinal and colonic stem cells are enabling the development of more reliable and robust systems for evaluating the impact of changes in the microbiome on gut health and screening potential drug candidates, including small molecules, biologics, and live biotherapeutics.

September 29, 2020

Accelerating Drug Development with Microphysiological Systems (MPS)

Current preclinical testing using assays based on cancer cells and animal models often results in high failure rates for drug candidates in the clinic. Microphysiological systems like Altis’s RepliGut™ human intestinal tissue model more accurately reflect human physiological environments, enabling more efficient and cost-effective drug discovery and development.